Vipivotide Tetraxetan
A PSMA-seeking molecule that delivers radiation directly to prostate cancer cells
Vipivotide tetraxetan carries radioactive lutetium-177 to cells that display PSMA, a protein found on most prostate cancers. Approved as Pluvicto in 2022 after the VISION trial, it is given intravenously every six weeks to men whose PSMA PET scan shows the target.
Manufacturer's recommended dosing (FDA label): 7.4 GBq (200 mCi), Every 6 weeks, Intravenous Details ↓
Recommended Dosing
Manufacturer's recommended dosing (FDA label)
From the prescribing information. Other doses studied, if any, are in the full dosing data below.
Used in human trials
No manufacturer dose exists for this use: these are amounts given in published trials, not recommendations.
What is it?
Prostate-specific membrane antigen (PSMA) sits on the surface of most prostate cancer cells, often at far higher levels than on normal tissue. That makes it a target for 'theranostics': one PSMA-binding molecule labelled for imaging finds the cancer on a PET scan, and a relative labelled for treatment delivers radiation to the same cells. Vipivotide tetraxetan, known in research as PSMA-617, is the treatment half; gozetotide is the imaging half.
The molecule is not a classic peptide. Its PSMA-binding part is a peptidomimetic glutamate-urea-lysine motif, joined through a linker to DOTA, a cage that holds lutetium-177. Lutetium-177 emits beta particles that travel only millimetres, damaging the cell it sits on and its neighbours. The drug leaves the body mainly through the kidneys, with a terminal elimination half-life of 41.6 hours.
In the VISION trial of 831 men with heavily pretreated metastatic castration-resistant prostate cancer, adding it to standard care extended median survival from 11.3 to 15.3 months. It was approved as Pluvicto in March 2022, and later trials moved it earlier; the current label also covers hormone-sensitive disease given with an androgen receptor pathway inhibitor. The label warns of radiation exposure, low blood counts, kidney toxicity, harm to a fetus and infertility.
The trials since VISION show where it helps and where the evidence is thinner. Against cabazitaxel chemotherapy in TheraP, PSA responses were far more common (66% against 37%) with fewer severe side effects, but survival ended up similar. In PSMAfore, before chemotherapy, it delayed scan-based progression (9.3 against 5.6 months), but most of the comparison group later crossed over to it and overall survival did not differ significantly. In hormone-sensitive disease, PSMAddition randomised 1,144 men to standard hormonal therapy with or without it and cut the risk of scan-based progression or death by 28%, with more grade 3 or worse side effects (51% against 43%).
Who receives it depends on a scan. Patients must show enough PSMA on a PET scan, usually with a gallium-68 PSMA tracer such as gozetotide, and in TheraP the men excluded for low PSMA did worse overall. Dry mouth is common because salivary glands also take up the drug; blood counts and kidney function are monitored through treatment.
Recent work is mostly about choosing patients and refining use. In 205 men with tumour sequencing, ATM alterations predicted better outcomes and CDK12 alterations worse ones, while BRCA2, often assumed to matter, did not. Kidney function, a long-standing worry with a renally cleared radioligand, declined no more than after docetaxel once baseline risk was accounted for, with the decline concentrated in men who already had kidney disease. Retreatment after an earlier course produced responses in some of 20 men without severe toxicity, and the same ligand carrying terbium-161 delivered high tumour doses in early dosimetry. Not every combination helps: a week of enzalutamide around each cycle did not improve results in a small phase 2 trial.
Mechanism of Action
Pluvicto is a delivery system: a small PSMA-seeking molecule carries a radioactive atom to prostate cancer cells.
PSMA binding
A glutamate-urea-lysine motif binds prostate-specific membrane antigen, which most prostate cancer cells carry at high levels; the drug is then taken into the cell.
Lutetium-177 beta radiation
DOTA holds lutetium-177, whose beta particles travel only millimetres, damaging the targeted cell and its immediate neighbours.
Theranostic pairing
The same PSMA target is imaged first with a gallium-68 tracer such as gozetotide; only patients whose tumours light up are treated.
Off-target uptake
Salivary glands and kidneys also take up PSMA ligands, explaining dry mouth and the label's kidney monitoring; it leaves the body mainly in urine, with a terminal half-life of 41.6 hours.
Published Research
The trials behind Pluvicto, read from their PubMed abstracts.
VISION phase 3, 831 men
In men with PSMA-positive metastatic castration-resistant prostate cancer after hormone tablets and chemotherapy, adding it to standard care extended median imaging-based progression-free survival from 3.4 to 8.7 months and overall survival from 11.3 to 15.3 months. Grade 3 or worse adverse events were more common (52.7% against 38.0%), but quality of life was not worsened.
PSMAfore phase 3: before chemotherapy
In 468 chemotherapy-naive men who had progressed once on a hormone tablet, median radiographic progression-free survival was 9.3 months on lutetium-177 PSMA-617 against 5.6 months on a switch of hormone tablet. Grade 3 to 5 adverse events were less common, 36% against 48%.
PSMAfore: final survival analysis
Median overall survival was 24.5 months against 23.1 months, not a significant difference; 60% of the comparison group crossed over to the drug, and adjusting for that gave a hazard ratio of 0.59. Dry mouth occurred in 59.5% and anaemia in 27.3%.
TheraP phase 2: against cabazitaxel
In 200 men who would otherwise have received cabazitaxel chemotherapy, PSA fell by at least half in 66% on lutetium-177 PSMA-617 against 37% on cabazitaxel, with fewer grade 3 or 4 adverse events (33% against 53%).
TheraP: overall survival
After a median of 35.7 months, survival was similar in the two groups (restricted mean 19.1 against 19.6 months). Men excluded because their scans showed too little PSMA did worse, with a restricted mean of 11.0 months.
ENZA-p phase 2: with enzalutamide
In 162 men starting treatment for castration-resistant disease, adding lutetium-177 PSMA-617 to enzalutamide extended median PSA progression-free survival from 7.8 to 13.0 months. Grade 3 to 5 events were similar, 40% against 41%; dry mouth affected 40% in the combination group.
PSMAddition phase 3: hormone-sensitive disease
In 1,144 men with PSMA-positive metastatic hormone-sensitive prostate cancer, adding lutetium-177 PSMA-617 to standard hormonal therapy reduced radiographic progression or death by 28% (HR 0.72); grade 3 or worse adverse events affected 51% against 43%.
Which tumour mutations predict response
In 205 men treated at one US centre, ATM alterations (12.7%) were linked to more PSA responses and longer progression-free and overall survival (hazard ratio for death 0.39), CDK12 alterations to markedly worse outcomes, and BRCA2 to neither; a pooled analysis kept ATM as favourable and TP53 and AR alterations as unfavourable.
Kidney function against chemotherapy
After propensity adjustment, kidney function six months after 3 to 6 cycles of lutetium-177 PSMA-617 declined no more than after docetaxel; decline was concentrated in men with chronic kidney disease at the start.
Retreatment after an earlier course
Of 589 men treated at one centre, 20 received a second course after at least two earlier cycles; some had PSA and imaging responses, with grade 2 kidney toxicity in one and grade 2 anaemia in three, and no grade 3 or 4 events. The design is retrospective and small.
Adding a week of enzalutamide (Lu-PRIME)
In a single-arm phase 2 trial of 20 heavily pretreated men, enzalutamide 160 mg/day for 7 days before and after each dose did not meaningfully improve results: PSA response 40%, median radiographic progression-free survival 4.0 months.
The same ligand with terbium-161
In 15 men given the PSMA-617 ligand carrying terbium-161 (about 6.0 GBq per cycle), dosimetry showed high tumour doses (about 5.95 Gy/GBq) with kidney and salivary doses giving tumour-to-organ ratios of about 10 and 16.
Dosing Data
Pluvicto is given only in specialist nuclear medicine settings: an intravenous dose of 7.4 GBq (200 mCi) every 6 weeks for up to 6 doses, after a PSMA PET scan confirms eligibility.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
The approved product, as its label describes it:
- Pluvicto (lutetium lu 177 vipivotide tetraxetan injection): Injection: 1,000 MBq/mL (27 mCi/mL) at calibration time in a single-dose vial containing 7.4 GBq (200 mCi) ± 10% at administration time. Forms the label lists: single-dose vials.
Source: Pluvicto (lutetium lu 177 vipivotide tetraxetan injection) label, section 3 (DailyMed version 5, effective August 12, 2026).
Mixing a vial: a worked example
Nothing to mix at home, and no syringe units to work out: Vipivotide Tetraxetan is a radioactive drug, prepared and given in nuclear-medicine departments, and its dose is an amount of radioactivity (MBq or GBq), not a weight.
This page's dosing note: “Pluvicto doses are radioactivity (GBq), dispensed ready to infuse by a radiopharmacy; there is nothing to reconstitute.”
Its label says: “Radiopharmaceuticals, including PLUVICTO, should be used by or under the control of healthcare providers who are qualified by specific training and experience in the safe use and handling of radiopharmaceuticals, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radiopharmaceuticals.”
Source: this page's own note in Dosing Data below; Pluvicto (lutetium lu 177 vipivotide tetraxetan injection) label, section 2 (DailyMed version 5, effective August 12, 2026); the amount of each dose row in Dosing Data below.
Storage before and after mixing
Before mixing or first use: “Store below 30°C (86°F).” “Store in the original package to protect from ionizing radiation (lead shielding).” “Store PLUVICTO in accordance with local and federal laws on radioactive materials.”
After mixing or first use: the label sentences we read say nothing separate about this.
Source: Pluvicto (lutetium lu 177 vipivotide tetraxetan injection) label, sections 16 and 2 (DailyMed version 5, effective August 12, 2026).
How it is taken
As the approved label gives it: Intravenous (Every 6 weeks; Label dose).
Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: a half-life of 41.6 hours, terminal elimination (label 12.3). After about five half-lives almost none is left.
How long the doses were given: Label dose: Up to 6 doses, or until progression or unacceptable toxicity.
When effects appear: unknown; no source on this page gives a time to effect for Vipivotide Tetraxetan. Results reported in the studies are under Published Research.
Source: half-life: Pluvicto prescribing information, section 12.3 (DailyMed set 14908037, effective August 12, 2026); Manufacturer's recommended dosing (FDA label), the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: Dry mouth, from uptake in the salivary glands; Fatigue and nausea; Anaemia and other low blood counts, monitored before each dose; More grade 3 or worse adverse events than hormonal therapy alone in PSMAddition (51% against 43%). Full list and cautions ↓
When the label says to stop or get help:
- Myelosuppression: Perform complete blood counts. Withhold, reduce dose, or permanently discontinue PLUVICTO based on severity. ( 2.4, 5.2 ) Renal Toxicity: Advise patients to remain well hydrated and to urinate frequently. Perform kidney function laboratory tests.
Source: Pluvicto (lutetium lu 177 vipivotide tetraxetan injection) label, boxed warning and section 5 (DailyMed version 5, effective August 12, 2026); the Side Effects section below (“From the trials above”).
Interactions
- various drugs, reviewed across 83 studies of therapeutic radiopharmaceuticals: interactions reported, most absent from product information and most at low evidence levels (88% CEBM level 3 or 4); the abstract does not list Pluvicto-specific pairs
Every peptide's record, with its source: the interaction matrix.
Source: human study, PMID 41746558.
Checking what you bought
Unknown: no published independent test of Vipivotide Tetraxetan products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: FDA Approved (Approved in the US as Pluvicto (lutetium Lu 177 vipivotide tetraxetan), NDA 215833, on March 23, 2022 (Novartis)). Sport: Not on the 2026 List.
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the trials above.
Contraindications & Cautions
Warnings from the Pluvicto label (DailyMed, effective August 12, 2026).
Legal Status
Vipivotide tetraxetan is approved in the US as Pluvicto, given only by specialist centres licensed to handle radioactive drugs.
Frequently Asked Questions
?What is Pluvicto?
Lutetium Lu 177 vipivotide tetraxetan: a molecule that binds PSMA on prostate cancer cells and carries radioactive lutetium-177 to them. It is given intravenously every six weeks.
?Who can receive it?
Men with PSMA-positive metastatic prostate cancer, confirmed on a PSMA PET scan such as one using gozetotide, in the settings its label describes.
?Is it a peptide?
Not exactly. Its PSMA-binding part is a peptidomimetic glutamate-urea-lysine motif, so we class it as a peptidomimetic rather than a peptide.
?Does Pluvicto work before chemotherapy?
It delayed scan-based progression in PSMAfore (9.3 against 5.6 months), but overall survival did not differ significantly, partly because most comparison patients crossed over to it.
?Why do I need a PSMA scan first?
Only tumours with enough PSMA take up the drug; the scan selects patients, and in TheraP men excluded for low PSMA did worse.
?Is Pluvicto a peptide?
Not a classic one. Its PSMA-binding part is a peptide-like glutamate-urea-lysine motif, linked to a DOTA cage that holds the radioactive lutetium-177; it is grouped with peptide radioligands because it works the same way.
?Does Pluvicto make me radioactive?
For a while. The label sets precautions after each dose to limit radiation exposure to caregivers and others, such as limiting close contact for a period; the treatment team gives the specific instructions.
?Who makes Pluvicto?
Drugs@FDA lists Novartis as the sponsor; FDA approved it on March 23, 2022 (NDA 215833), and its label now also covers earlier, hormone-sensitive disease.
References
- [fda] US FDA, Drugs@FDA (openFDA): PLUVICTO (lutetium Lu 177 vipivotide tetraxetan), NDA 215833, original approval March 23, 2022, prescription. Read October 3, 2026.
- [fda-pi] FDA. Pluvicto (lutetium Lu 177 vipivotide tetraxetan) US prescribing information (DailyMed set 14908037-2892-4d98-a053-253ce35afb1a, version 5, effective August 12, 2026). Read October 3, 2026.
- [pubmed] Sartor O, et al. "Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer." N Engl J Med, 2021;385(12):1091-1103. PMID: 34161051.
- [pubmed] Morris MJ, et al. "(177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial." Lancet, 2024;404(10459):1227-1239. PMID: 39293462.
- [pubmed] Fizazi K, et al. "Final overall survival and safety analyses of the phase III PSMAfore trial of [(177)Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer." Ann Oncol, 2025;36(11):1319-1330. PMID: 40680993.
- [pubmed] Hofman MS, et al. "[(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial." Lancet, 2021;397(10276):797-804. PMID: 33581798.
- [pubmed] Hofman MS, et al. "Overall survival with [(177)Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial." Lancet Oncol, 2024;25(1):99-107. PMID: 38043558.
- [pubmed] Emmett L, et al. "[(177)Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial." Lancet Oncol, 2024;25(5):563-571. PMID: 38621400.
- [pubmed] Tagawa ST, et al. "[(177)Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial." Lancet, 2026;408(10557):793-807. PMID: 42561994.
- [pubmed] Mahajan V, et al. "Association of ATM Alterations with Outcomes After (177)Lu-PSMA-617 Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer." J Nucl Med, 2026. PMID: 42785951.
- [pubmed] Sheheryar N, et al. "Renal Function Decline After (177)Lu-PSMA-617 Versus Taxane-Based Chemotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Propensity Score Analysis." J Nucl Med, 2026. PMID: 42785953.
- [pubmed] Belge Bilgin G, et al. "PSMA-RECAP: [(177)Lu]Lu-PSMA-617 retreatment in metastatic castration-resistant prostate cancer." Front Oncol, 2026;16:1831393. PMID: 42729213.
- [clinical-trial] Aggarwal P, et al. "[(177)Lu]Lu-PSMA-617 Plus Short-Course Priming With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Single-Arm Phase 2 Trial (Lu-PRIME)." Prostate, 2026. PMID: 42732593.
- [pubmed] Schaefer-Schuler A, et al. "Organ and tumor dosimetry of [(161)Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC." Eur J Nucl Med Mol Imaging, 2026. PMID: 42709069.
Sources & Citations
Studies were read from their PubMed records; regulatory sources are listed below, read October 3, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.